Gilead Sciences announced positive topline results from the Phase 3 ARTISTRY-2 trial on December 15, 2025 and reported by Drugs.com, marking a significant advancement in HIV treatment options. The trial evaluated a novel once-daily single-tablet regimen combining bictegravir 75 mg and lenacapavir 50 mg (BIC/LEN) against BIKTARVY, an established HIV treatment, in adults with virologically suppressed HIV.
Trial Success and Key Findings
The double-blind ARTISTRY-2 trial successfully met its primary endpoint, demonstrating that BIC/LEN was statistically non-inferior to BIKTARVY in preventing virologic failure. The primary efficacy measure focused on the percentage of participants with HIV-1 RNA levels below 50 copies/mL at Week 48, using the FDA snapshot algorithm as the standard measurement. Importantly, the investigational combination was generally well tolerated with no significant or new safety concerns identified throughout the trial.
The Innovation Behind the Combination
The investigational BIC/LEN regimen represents a unique pairing of two distinct antiretroviral agents with complementary mechanisms of action. Bictegravir is a globally recommended integrase strand transfer inhibitor (INSTI) known for its high barrier to resistance, making it a standard-of-care component in HIV treatment. Lenacapavir, however, represents groundbreaking innovation as the first-in-class capsid inhibitor, functioning through a multi-stage mechanism that inhibits HIV at multiple points in its viral lifecycle. Crucially, lenacapavir exhibits no overlapping resistance patterns with existing drug classes, addressing a critical challenge in long-term HIV management.
Transforming the HIV Treatment Landscape
Dr. Eric Meissner, Associate Professor and Director of HIV and Hepatitis Patient Care at the Medical University of South Carolina, emphasized the clinical significance of these results. He noted that the findings demonstrate how the novel combination achieves a comparable efficacy profile to guideline-recommended treatments while potentially expanding patient options. The consolidation of two potent agents into a single tablet addresses both efficacy and adherence challenges, as simplified regimens typically improve patient compliance and treatment outcomes.
Clinical Trial Design
ARTISTRY-2 enrolled adults with HIV who were virologically suppressed and randomly assigned them in a 2:1 ratio to either switch to BIC/LEN or continue on BIKTARVY. This design provided a robust comparison of switching efficacy, with secondary endpoints including virologic suppression rates, CD4 cell count changes, and adverse event profiles measured at Week 48.
Regulatory Path Forward
Gilead plans to submit comprehensive Phase 3 data from both ARTISTRY-2 and the earlier ARTISTRY-1 trial (which demonstrated non-inferiority to multi-tablet regimens in treatment-naive patients) to regulatory authorities. The company intends to present detailed findings at future scientific congresses, though lenacapavir combined with bictegravir remains investigational and has not yet received FDA approval.
Broader Implications
This development reflects Gilead’s three-decade commitment to HIV innovation. The combination leverages lenacapavir’s recent recognition as TIME’s Best Invention and Science magazine’s 2024 Breakthrough of the Year, incorporating this revolutionary capsid inhibitor into practical clinical treatment. The single-tablet regimen addresses a critical gap in HIV management by offering people living with HIV a simplified, potent option that maintains virologic suppression while reducing daily medication burden.
The ARTISTRY trials represent an important step toward personalized HIV treatment, ultimately aiming to improve health outcomes and reduce viral transmission across diverse patient populations worldwide.
